Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Published Online: 2015-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alessandro Testori•Alexander M M Eggermont•Axel Hoos•Caroline Robert•Cyril Konto•Céleste Lebbé•Gaetan de Schaetzen•Henrik Schmidt•Jean-Jacques Grob•Jedd D Wolchok•Jeffrey S Weber•Jon M Richards•Michael Smylie•Michele Maio•Omid Hamid•Paolo A Ascierto•Ravichandra Karra Gurunath•Reinhard Dummer•Stefan Suciu•Vanna Chiarion-Sileni•Veerle de Pril•Virginia Ferraresi
